BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 395094)

  • 1. Influence of insulin infusion kinetics of an artificial beta cell on blood glucose control in insulin-dependent diabetics.
    Kerner W; Beischer W; Maier V; Pfeiffer EF
    Horm Metab Res Suppl; 1979; (8):71-80. PubMed ID: 395094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin treatment and state of control before, during, and after connection to a glucose controlled insulin infusion system (Biostator).
    Christiansen JS; Svendsen PA; Deckert T
    Horm Metab Res Suppl; 1979; (8):131-4. PubMed ID: 395069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control algorithms for artificial beta cell.
    Clemens AH
    Horm Metab Res Suppl; 1979; (8):35-8. PubMed ID: 395086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic study of the blood viscosity of insulin-dependent diabetics by means of an artificial pancreas.
    Drouin P; Rousselle D; Pointel JP; Voisin G; Stoltz JF; Clemens AH; Debry G
    Horm Metab Res Suppl; 1979; (8):107-10. PubMed ID: 395064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attempts at perfect normalization of glucose tolerance test of severe diabetics by artificial beta cell.
    Kerner W; Thum C; Tamás G; Beischer W; Clemens AH; Pfeiffer EF
    Horm Metab Res; 1976 Jul; 8(4):256-61. PubMed ID: 783030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal blood sugar control in labile diabetics using a portable open-loop insulin infusion system with a flexible program.
    Froesch ER; Blatter G; Morell B
    Horm Metab Res Suppl; 1979; (8):198-201. PubMed ID: 395079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of continuous physiologic hyperinsulinemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans.
    Saccà L; Sherwin R; Hendler R; Felig P
    J Clin Invest; 1979 May; 63(5):849-57. PubMed ID: 447832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of three days of blood glucose normalization by means of an "artificial endocrine pancreas" on the concentrations of growth hormone, glucagon, and cortisol in juvenile diabetics.
    Schock A; Schultz M; Kerner W; Maier V; Pfeiffer EF
    Horm Metab Res Suppl; 1979; (8):93-6. PubMed ID: 395097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous intravenous insulin therapy with a miniaturized open-loop system.
    Renner R; Hepp KD; Mehnert H; Franetzki M
    Horm Metab Res Suppl; 1979; (8):186-90. PubMed ID: 395077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The artificial beta cell (Biostator) in the adjustment of instable diabetics--results after 20 months.
    Beyer J; Wolf E; Cordes U; Hassingen W
    Horm Metab Res Suppl; 1979; (8):127-31. PubMed ID: 395068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Closed-loop system in evaluation of insulin infusion rates for an open-loop system.
    Kølendorf K; Christiansen JS; Svendsen PA; Bojsen J
    Horm Metab Res Suppl; 1979; (8):205-6. PubMed ID: 395082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a perfusion syringe (Mill Hill Infusor) and a glucose-controlled insulin infusion system in the regulation of diabetes mellitus.
    Stavljenić A; Granić M; Topić B; Skrabalo Z
    Horm Metab Res Suppl; 1979; (8):207-11. PubMed ID: 395083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic studies during normoglycaemic clamping of insulin-dependent diabetics using a glucose-controlled insulin infusion system.
    Nattrass M; Alberti KG; Buckle AL; Cluett B; Jaspan JB; Noy GA; Stubbs WA; Walton R
    Horm Metab Res Suppl; 1979; (8):86-92. PubMed ID: 395096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of an artificial beta cell in surgery.
    Horwitz DL; Schwartz SS
    Horm Metab Res Suppl; 1979; (8):156-8. PubMed ID: 395072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of cortisol circadian variations on insulin need and delivery in insulin-dependent diabetics. Assessment by the artificial beta cell.
    Altomare E; Moulin JP; Tavares S; Bourelly N; Lassmann V; Vague P
    Horm Metab Res Suppl; 1979; (8):110-5. PubMed ID: 395065
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical application of pre-programmed insulin infusion: continuous subcutaneous insulin therapy with a portable infusion system.
    Pickup JC; Viberti GC; Keen H; Parsons JA; Alberti KG
    Horm Metab Res Suppl; 1979; (8):202-4. PubMed ID: 395081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of glucose-controlled insulin infusion system for improvement of subcutaneous insulin regimen.
    Irsigler K; Kritz H; Kaspar L; Brändle J; Franetzki M
    Horm Metab Res Suppl; 1979; (8):134-40. PubMed ID: 395070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 24-hour insulin requirements in IDDM patients during control by an artificial betacell and during conventional therapy.
    Christiansen JS; Svendsen PA; Mathiesen E; Rubin P; Deckert T
    Horm Metab Res; 1981 Oct; 13(10):537-41. PubMed ID: 7028586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of daily insulin requirements in diabetics with an artificial endocrine pancreas.
    Lambert AE; Buysschaert M; Lambotte L
    Horm Metab Res Suppl; 1979; (8):120-7. PubMed ID: 395067
    [No Abstract]   [Full Text] [Related]  

  • 20. The external artificial pancreas: an instrument to induce remissions in severe recent juvenile diabetes. Comparison with a preprogrammed insulin infusion system.
    Mirouze J; Selam JL; Pham TC; Orsetti A
    Horm Metab Res Suppl; 1979; (8):141-5. PubMed ID: 395071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.